FORM 6 - K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
For the month of January 2000
Commission File Number 0-29350
VASOGEN INC.
(Translation of Registrant's name into English)
2155 Dunwin Drive, Suite 10, Mississauga, Ontario, L5L 4M1
(Address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20 - F or Form 40 - F.)
Form 20 - F [ X ] Form 40 - F [ ]
(Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)
Yes [ ] No [ X ]
This Form 6-K consists of:
A press release issued by Vasogen Inc. on January 11, 2000, titled:
"Vasogen Appoints Prominent U.S. Immunologist to Scientific Advisory Board"
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VASOGEN INC.
By /s/Christopher Waddick
----------------------
(Name: Christopher Waddick)
(Title: Vice-President, Finance & CFO)
Date: January 12, 2000
<PAGE>
Vasogen Inc. INVESTOR CONTACT
2155 Dunwin Drive, Suite 10 Trevor Burns
Mississauga, ON, Canada L5L 4M1 Investor Relations
tel (905) 569-2265 fax (905) 569-9231 tel (905) 569-9065
http://www.vasogen.com e-mail [email protected]
- --------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
VASOGEN APPOINTS PROMINENT U.S. IMMUNOLOGIST TO SCIENTIFIC ADVISORY BOARD
Toronto, Ontario (January 11, 2000) -- Vasogen Inc. (TSE:VAS; AMEX:MEW) is
pleased to announce the appointment of Dr. David Wofsy to its Scientific
Advisory Board. Dr. Wofsy is the George A. Zimmerman Distinguished Professor of
Medicine and Microbiology/Immunology and Director of the Clinical Trials Center
at the University of California, San Francisco. He also serves as Chief of the
Rheumatology Section at the San Francisco Veterans Administration Medical
Center.
Dr. Wofsy is a leading authority on the cellular and molecular mechanisms
underlying autoimmune diseases. Based on extensive research, he has developed
novel approaches to the use of immune modulation therapies in the treatment of
this very common group of diseases. Much of Dr. Wofsy's research has been on
systemic lupus erythematosus (SLE), an autoimmune disease, where he was the
first to demonstrate the key pathological role of CD4+T cells in a standard
animal model of this disease. His most recent research has extended to
additional novel methods for blocking T cell activation. These approaches are
currently in clinical trials. He is the author of numerous key publications and
book chapters, and serves on the editorial and advisory boards of several major
immunology journals. He has received many distinguished awards and his visiting
professorships include Harvard University and the National Institutes of Health.
Dr. Eldon Smith, Vasogen's Vice President of Scientific Affairs stated: "as
evidence mounts that Vasogen's therapies are working through modulation of the
immune system, the appointment of an immunologist of Dr. Wofsy's background and
stature to our Scientific Advisory Board is especially timely. His extensive
knowledge of immune modulation as a therapeutic strategy will be invaluable to
Vasogen as we move forward with our clinical trials program".
Vasogen is focused on developing immune modulation therapies to advance the
treatment of cardiovascular, autoimmune and related inflammatory diseases.
These therapies are designed to target fundamental disease-causing events,
providing safe, effective treatment.
Statements contained in this press release, including those pertaining to
scientific and clinical research, commercialization plans, strategic alliances,
and intellectual property protection, other than statements of historical fact,
are forward-looking statements subject to a number of uncertainties that could
cause actual results to differ materially from statements made.
